- Home
- STG vs AVTX Comparison
STG vs AVTX Comparison
Compare STG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | AVTX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 248.3M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | STG | AVTX |
|---|---|---|
| Price | $6.25 | $17.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | 4.0K | ★ 302.8K |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.28 | $3.39 |
| 52 Week High | $15.00 | $20.72 |
Technical Indicators
Market Signals| Indicator | STG | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 48.21 |
| Support Level | $5.84 | $15.49 |
| Resistance Level | $6.12 | $18.54 |
| Average True Range (ATR) | 0.30 | 1.17 |
| MACD | 0.04 | -0.28 |
| Stochastic Oscillator | 72.37 | 44.93 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).